1-7 of 7
Eric Laille, MS
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I/II Multicenter Study of Romidepsin in Japanese Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Michinori Ogura, Dai Maruyama, MD PhD, Kensei Tobinai, MD, PhD, Toshiki Uchida, MD PhD, Kiyohiko Hatake, MD PhD, Masafumi Taniwaki, MD PhD, Kiyoshi Ando, MD PhD, Kunihiro Tsukasaki, MD, Takashi Ishida, MD PhD, Naoki Kobayashi, MD PhD, Kenichi Ishizawa, MD PhD, Yoichi Tatsumi, Koji Kato, MD PhD, Toru Kiguchi, MD PhD, Takayuki Ikezoe, MD PhD, Eric Laille, MS, Tokihiro Ro, MS, Hiromi Tamakoshi, MBA, Sanae Sakurai, MS, Tomoko Ohtsu, MD PhD
Journal: Blood
Blood (2016) 128 (22): 3012.
https://doi.org/10.1182/blood.V128.22.3012.3012
Published: 2016
Journal Articles

CC-486 (Oral Azacitidine) Following Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)

Basem M. William, MD, Marcos de Lima, MD, Betul Oran, MD, Richard Champlin, MD, Esperanza B Papadopoulos, MD, Sergio Giralt, MD, Bart L. Scott, MD, Joel Hetzer, PhD, Xiwei Wang, PhD, Eric Laille, MS, Barry S. Skikne, MD, Charles Craddock, MDPhD
Journal: Blood
Blood (2014) 124 (21): 990.
https://doi.org/10.1182/blood.V124.21.990.990
Published: 2014
Journal Articles

CC-486 in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), or Chronic Myelomonocytic Leukemia (CMML): Safety, Tolerability, and Response

Michael R. Savona, MD, Kathryn Kolibaba, MD, Paul Conkling, MD, Edwin C. Kingsley, MD, Carlos Becerra, MD, John Morris, MD, Robert M. Rifkin, MD, Eric Laille, MS, Amy Kellerman, BA, Stacey M. Ukrainskyj, BSN,RN, Qian Dong, MS, Barry S. Skikne, MD
Journal: Blood
Blood (2014) 124 (21): 4638.
https://doi.org/10.1182/blood.V124.21.4638.4638
Published: 2014
Journal Articles

Extended Dosing of Oral Azacitidine (CC-486) for 14 and 21 Days Provides More Effective Methylation Reversal Than a 7-Day Schedule

Eric Laille, MS, Tao Shi, PhD, Guillermo Garcia-Manero, MD, Christopher R. Cogle, MD, Steven D. Gore, MD, Keshava J. Kumar, PhD, Barry S. Skikne, MD, Kyle J. MacBeth, PhD
Journal: Blood
Blood (2012) 120 (21): 1337.
https://doi.org/10.1182/blood.V120.21.1337.1337
Published: 2012
Journal Articles

Oral Azacitidine (AZA) Activity in Patients with Acute Myelogenous Leukemia (AML)

Steven D. Gore, MD, Christopher R. Cogle, MD, Barry Skikne, MD, Eric Laille, MS, Tao Shi, PhD, Kyle J. MacBeth, PhD, Heidi Giordano, MA, MBA, Guillermo Garcia-Manero
Journal: Blood
Blood (2011) 118 (21): 1546.
https://doi.org/10.1182/blood.V118.21.1546.1546
Published: 2011
Journal Articles

A 2-Part Phase I Study in Patients with Solid or Hematologic Malignancies: Dose Proportionality of Subcutaneous (SC) Azacitidine (AZA) and Pharmacokinetics of SC AZA in Patients with Severe Renal Impairment,

Eric Laille, MS, Alain C. Mita, MD, Sanjay Goel, MD, MS, Nashat Y. Gabrail, MD, Joseph Schwarz, MBA, CL Beach, PharmD
Journal: Blood
Blood (2011) 118 (21): 3480.
https://doi.org/10.1182/blood.V118.21.3480.3480
Published: 2011
Journal Articles

Evaluation of Oral Azacitidine Using Extended Treatment Schedules: A Phase I Study

Guillermo Garcia-Manero, MD, Steven D. Gore, MD, Christopher R. Cogle, MD, Elias J. Jabbour, MD, M. Renee Ward, MD, PhD, Kyle J. MacBeth, PhD, Eric Laille, MS, Heidi Giordano, MA, Hagop M. Kantarjian, MD, Barry S. Skikne, MD
Journal: Blood
Blood (2010) 116 (21): 603.
https://doi.org/10.1182/blood.V116.21.603.603
Published: 2010